Schering Corporation

Merck Sharp + Dohme Corp.

Pharmacopeia Drug Discovery, Inc.

Pharmacopeia Inc.

Robert Mazzola

Zhaoning Zhu

Brian Alexander McKittrick

William J Greenlee

Andrew William Stamford

Tao Guo

Thuy X H Le

Yuanzan C Ye

Neng-Yang Shih

Joseph A Kozlowski

Jared N Cumming

Elizabeth M Smith

Corey Strickland

Ulrich Iserloh

Brian J Lavey

Yusheng Wu

Zhuyan Guo

Suresh D Babu

Lingyan Wang

Johannes H Voigt

John P Caldwell

Zhong-Yue Sun

Kurt William Saionz

Rachael Catherine Hunter

Gang Qian

Lisa Sinning

Michelle Lee Morris

Dawit Tadesse

Duane A Burnett

Ying Huang

Guoqing Li

Jing Su

Thavalakulamgara K Sasikumar

Yuefei Shao

Huizhong Gu

Li Qiang

Brian Mckittrick

Rachael C Hunter

X H Le Thuy

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.

Heterocyclic aspartyl protease inhibitors

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein

Substituted isoindolines as aspartyl protease inhibitors

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-&#x3b1; or combinations thereof.

Compounds for the treatment of inflammatory disorders

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.

The present invention provides compounds, which, are novel antagonists for D/Dreceptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D/Dreceptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

[object Object]

This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-&#x3b1; or combinations thereof.

Growing community of inventors

Stewartsville, NJ, United States of America

Robert Mazzola